Smajo Osmanovic is an Ophthalmology physician affiliated with Arlington Dermatology. OpenAlex indexes 29 publications with 506 citations (h-index 12); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1604 W Central Rd
Arlington Heights, IL 600052407
Telephone
847-394-1414Provider last certified this registry record 29 May 2024.
Clinical trials
- The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye
Sponsor: Summa Health System
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
19 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20255 payments
- Amgen Inc.Program year20252 payments
- Genentech USA, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
73.8%Prostaglandin Analog48.5%Latanoprost89%Lumigan9%Travoprost2%Part D<11 patientsCarbonic Anhydrase Inhibitor12.3%Dorzolamide Hcl44%Dorzolamide-Timolol44%Simbrinza7%Brinzolamide6%Part D<11 patients+ 4 more classes in this area
Cardiovascular
11.4%Beta blocker11.4%Timolol Maleate100%Part D≥61 patientsAnti-infectives
11.3%Macrolide6.1%Erythromycin100%Part D≥86 patientsTetracycline-class Drug5.2%Doxycycline Hyclate69%Minocycline Hcl31%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A Prospective, Post-Market, Multicenter Trial (CHEETAH) Suggested TearCare® System as a Safe and Effective Blink-Assisted Eyelid Device for the Treatment of Dry Eye Disease
DOAJ (DOAJ: Directory of Open Access Journals)
2020 - Surface Imaging of ParasolTM and QuintessTM Punctal Plugs following extrusion
Investigative Ophthalmology & Visual Science
2019 - Bimatoprost-Induced Periocular Skin Hyperpigmentation2015
Similar KOLs
Other experts from the same institution or the same specialty.
Ali Bijani
Babol University of Medical Sciences
Hamid Asayesh
Ayatollah Boroujerdi University
John J. Huang
Isfahan University of Medical Sciences
Fotis Topouzis
National University of Singapore
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”